Skip to main content
Mauna Kea Technologies logo

Mauna Kea Technologies — Investor Relations & Filings

Ticker · MKEA ISIN · FR0010609263 LEI · 5493007KMDG4MFIGJJ63 PA Manufacturing
Open in API
Filings indexed 774 across all filing types
Latest filing 2019-01-04 Capital/Financing Update
Country FR France
Listing PA MKEA

About Mauna Kea Technologies

https://www.maunakeatech.com/en/

Mauna Kea Technologies is a medical device company that develops and markets the Cellvizio® platform, a real-time in vivo cellular imaging system. The platform utilizes Confocal Laser Endomicroscopy (CLE) technology, enabling physicians to visualize tissue at the cellular level during medical procedures. This "optical biopsy" is performed using flexible, miniature fiber-optic probes (Confocal Miniprobes™) that are compatible with standard endoscopes. The core function of Cellvizio® is to provide immediate microscopic visualization, which aids in accelerating diagnosis, informing treatment strategies, and improving the precision of therapeutic interventions. Key applications include gastroenterology (for conditions such as Barrett's esophagus and pancreatic cysts), interventional pulmonology (lung cancer diagnostics), urologic oncology, and neurosurgery. The technology supports enhanced surgical procedures, including real-time margin assessment, and is being integrated with robotic surgery and AI-assisted imaging systems.

Recent filings

Filing Released Lang Actions
Rachat d'actions / Contrat de liquidité Information relative au contrat de liquidité
Capital/Financing Update Classification · 99% confidence The document is titled "BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE" (Semi-annual balance sheet of the liquidity contract) and reports the status of a liquidity contract (market making agreement) as of December 31, 2018, comparing it to the previous semi-annual balance from June 30, 2018. This type of report details the assets (shares and cash) held under a liquidity provision agreement. This specific content—a periodic report on a market-making or liquidity provision contract—does not fit neatly into the standard SEC filings (10-K, IR, ER, etc.) or common corporate actions (DIV, CAP, MANG). It is a specific financial/regulatory disclosure related to market stability mechanisms. Given the options, it is a specialized financial disclosure. Since it is a periodic report detailing financial/contractual status, and not a general announcement of a report release (RPA) or a standard regulatory filing (RNS), it requires careful mapping. It is most closely related to ongoing financial monitoring or contractual obligations. In the context of the provided definitions, 'Capital/Financing Update' (CAP) is too broad, and 'Regulatory Filings' (RNS) is the best fit for specialized, non-standard periodic disclosures that don't match the other specific categories, especially since liquidity contracts are often subject to regulatory oversight.
2019-01-04 French
Communicated under the obligation to provide permanent information / Other communications
Capital/Financing Update Classification · 99% confidence The document is a press release dated November 19, 2018, announcing an amendment to an existing debt agreement with IPF Partners, specifically providing additional borrowing capacity of up to 10 million Euros. This content directly relates to changes in the company's financing structure and capital arrangements. Based on the provided definitions, this falls under 'Capital/Financing Update' (Code: CAP). It is not an Annual Report (10-K), an Earnings Release (ER), or a general Regulatory Filing (RNS), as it concerns a specific financing event.
2018-11-19 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Capital/Financing Update Classification · 99% confidence The document is an announcement dated November 19, 2018, detailing the signing of an amendment to a debt agreement with IPF Partners, allowing Mauna Kea Technologies to subscribe to up to 10 million euros of additional debt in tranches. This clearly relates to fundraising, financing activities, and changes to the capital structure (debt financing). This aligns directly with the definition of 'Capital/Financing Update' (Code: CAP). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it concerns a specific financing event.
2018-11-19 French
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release dated November 6, 2018, announcing positive clinical trial results (CONTACT 2 study) for the Cellvizio product regarding pancreatic cysts. It details study performance metrics (sensitivity, specificity) and quotes management and the lead investigator. This type of announcement, which communicates significant business or clinical developments outside of routine periodic financial reporting (like 10-K or IR), typically falls under general regulatory announcements or investor relations communications. Since it is not a formal financial report (10-K, IR), an earnings release (ER), or a specific management discussion (MDA), and it is a direct announcement of a major event (clinical data publication), it best fits the 'Regulatory Filings' (RNS) category as a general regulatory/material event disclosure, or potentially an Investor Presentation (IP) if it were structured as slides, but here it reads like a news release. Given the options, RNS serves as the best catch-all for material, non-standardized announcements. It is not a proxy statement (DEF 14A), a dividend notice (DIV), or a management change (MANG). It is a communication of clinical/business progress, making RNS the most appropriate classification for a general material announcement.
2018-11-06 French
Communicated under the obligation to provide permanent information / Other communications
Earnings Release Classification · 95% confidence The document is a press release dated November 6, 2018, announcing positive clinical trial results for the company's product, Cellvizio, specifically regarding its diagnostic performance in pancreatic cysts. It details study endpoints, compares results to the standard of care, includes quotes from the CEO and a lead physician, and provides contact information and a standard disclaimer. This format—announcing key financial or operational achievements outside of a formal periodic report (like 10-K or IR)—is characteristic of an Earnings Release (ER) or a general press release announcing significant operational news. Since it focuses on clinical trial success and diagnostic performance rather than just quarterly financial figures, it is best classified as an Earnings Release (ER) as it is the initial announcement of a major operational/performance milestone, or potentially a Regulatory Filing (RNS) if it were a mandatory disclosure. Given the structure and content (announcing results and performance metrics), ER is the most fitting category among the specific options, as it functions as a performance update. FY 2018
2018-11-06 English
Rapport Financier Semestriel 2018
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Rapport Financier Semestriel 2018' (2018 Half-Year Financial Report) and contains comprehensive financial statements, including the consolidated balance sheet, income statement, and management discussion and analysis for the six-month period ending June 30, 2018. It is a substantive financial report rather than an announcement or a summary, fitting the definition of an Interim/Quarterly Report. H2 2018
2018-09-21 French

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.